Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study
- PMID: 39626674
- PMCID: PMC11722090
- DOI: 10.1016/j.xcrm.2024.101835
Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study
Abstract
While HIV infection and clonal hematopoiesis (CH) have been linked with inflammatory dysregulation and an increased risk of aging-related comorbidities, their relationship with clinical geriatric syndromes has not been well defined. In the Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) study (NCT04641013), we measure associations between HIV and CH and geriatric syndromes. Of 345 participants (176 with HIV and 169 without HIV), 23% had at least one mutation associated with CH: 27% with HIV and 18% without HIV (p = 0.048). In adjusted analyses, HIV infection is independently associated with increased phenotypic age acceleration (coefficient 1.73, 95% confidence interval [CI] 0.3, 3.16) and CH is independently associated with being frail (vs. pre-frail/robust; odds ratio 2.38, 95% CI 1.01, 5.67) and with having reduced quality of life (coefficient -2.18, 95% CI -3.92, -0.44). Our findings suggest that HIV is associated with increased biological age and that CH may be used as a biomarker for adverse geriatric outcomes.
Keywords: HIV; aging-related comorbidities; clonal hematopoiesis; frailty; geriatric syndromes; multimorbidity; phenotypic age acceleration; quality of life.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.B. has received funding from Gilead Sciences and ViiV Healthcare for lecturing and traveling to scientific meetings and medical advisory boards. D.A.B. has received funding and travel grants from and served on advisory boards for ViiV Healthcare and Gilead. D.E.S. has received consultancy fees and lecturing honorarium from ViiV Healthcare and Gilead Sciences. J.F.H.’s institution has received reimbursement for her participation in advisory boards for Gilead Sciences and ViiV Healthcare. I.W.’s institution has received financial or in-kind support for his role in clinical studies from Moderna, CSL, MSD, Gilead, and ViiV. G.V.M. has received research funding from Gilead, AbbVie, Janssen, and ViiV, has served on advisory boards for AstraZeneca and ViiV, and has provided consultancy and received travel support from Gilead. M.N.P. has received research funding from ViiV, Janssen, and Gilead (awarded to institution), research support (in kind) from ViiV, Janssen, BMS, Verastem, ASTEX, Grifols, CSL Behring, Takeda, and Emergent (in kind, to institution) and has served on the advisory board for AstraZeneca and Gilead. P.Y. has received speaker honoraria from Astellas Pharma for unrelated projects.
Figures



References
-
- World Health Organization. Ageing and Health. Available at: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Access date May 7, 2024.
-
- World Health Organization. UN Decade of Healthy Ageing. Available at: https://www.who.int/initiatives/decade-of-healthy-ageing. Access date May 7, 2024.
-
- Shacter E., Weitzman S.A. Chronic inflammation and cancer. Oncology (Williston Park, NY) 2002;16:217–232. 229; discussion 230. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical